Bimatoprost

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
Dienstag, April 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.

Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma

Retrieved on: 
Montag, Dezember 18, 2023
IOP, Blood, Whistler, Glaucoma, NCX, Intraocular pressure, Ocular hypertension, Mayo Clinic, Bimatoprost, Nitric oxide, Patient, EVP, Clinical professor, Humour, Pharmaceutical industry

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering.

Key Points: 
  • Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering.
  • NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is our lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
  • Each subject will participate in the trial for ~8 days and will provide insight into the mechanism of action of NCX 470.
  • The Company is currently funded until the end of June 2024, exclusively on the basis of the development of NCX 470.

Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan

Retrieved on: 
Donnerstag, Dezember 14, 2023
IOP, Bimatoprost, Allergan, Inc., Glaucoma, Primate, Congress, Eye, Therapy, NCX, Intraocular pressure, Ocular hypertension, Nitric oxide, Patient, Pharmacology, Humour, Pharmaceutical industry

The publication “NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs” by Galli et al.

Key Points: 
  • The publication “NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm’s Canal Constructs” by Galli et al.
  • NCX 470 is designed to release both bimatoprost and NO into the eye to lower IOP by two pathways.
  • Measurements were taken on the fourth day and demonstrated that NCX 470 increased both outflow facility and uveoscleral outflow compared to vehicle.
  • Outflow facility was increased by both NCX 470 and bimatoprost compared to vehicle, with NCX 470 having a greater effect than bimatoprost.

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

Retrieved on: 
Montag, November 6, 2023
Actinium, Therapy, Ophthalmology, Organon, AMD, Merck, Acquisition, Schering-Plough, Research, Drug development, Bayer, University, Schizophrenia, Pembrolizumab, Knowledge management, AbbVie, Depression, University of Wales, Newport, Patient, Mirtazapine, Pharmaceutical industry, Volastra, Bimatoprost, Adverum Biotechnologies, Allergan

"We are excited to welcome David to Adverum’s Board of Directors.

Key Points: 
  • "We are excited to welcome David to Adverum’s Board of Directors.
  • He brings an exceptional breadth of experience and a track record of success in pharmaceutical R&D and has launched multiple transformative products throughout his career, notably in ophthalmology," stated Patrick Machado, J.D., board chair of Adverum Biotechnologies.
  • “On behalf of the management team at Adverum, I’d like to extend a warm welcome to David,” added Laurent Fischer, M.D., president and chief executive officer of Adverum.
  • from the University of Manchester and his Ph.D. from the University of Wales.

SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform

Retrieved on: 
Dienstag, Oktober 31, 2023
FDA, Intraocular pressure, Ocular hypertension, Glaucoma, IOP, Entrepreneurship, Phase, Clinical trial, Bimatoprost, Safety, Patient, Cataract, Spyglass, Pharmaceutical industry, Medical device, IOL

ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.

Key Points: 
  • ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts.
  • The SpyGlass platform is designed to be implanted at the time of routine cataract surgery and deliver multiple years of bimatoprost, to lower intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
  • “The initiation of our Phase I/II study is an exciting and significant milestone for the company,” said Malik Y. Kahook, M.D., Co-Founder, Executive Chair and President of SpyGlass Pharma™.
  • “We are enthusiastic about conducting this vital research and working with the FDA to advance our platform through clinical development,” said Patrick Mooney, CEO of SpyGlass Pharma™.

Antiglaucoma Drugs Global Market Report 2023

Retrieved on: 
Montag, Februar 20, 2023
Brimonidine/timolol, Bayer, 2020 Vision, Organization, Patent, Paratriathlon, Alcon, Government, Glaucoma, Korea Disease Control and Prevention Agency, Adrenaline, Bimatoprost, Johnson & Johnson, Merck & Co., Incidence, Patient, Geography, Travoprost, Pfizer, Novartis, Optic nerve, Risk, CDC, Dorzolamide/timolol, IOP, US, MedImmune, Inc. v. Genentech, Inc., USFDA, COVID-19, Overalls, Intraocular pressure, Carbonic anhydrase inhibitor, Pharmaceutical industry, Allergan, Brinzolamide

The global antiglaucoma drugs market will grow from $14.02 billion in 2022 to $15.04 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%.

Key Points: 
  • The global antiglaucoma drugs market will grow from $14.02 billion in 2022 to $15.04 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%.
  • The regions covered in the antiglaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The countries covered in the antiglaucoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
  • The antiglaucoma drug market research report is one of a series of new reports that provides antiglaucoma drug market statistics, including antiglaucoma drug industry global market size, regional shares, competitors with an antiglaucoma drug market share, detailed antiglaucoma drug market segments, market trends and opportunities, and any further data you may need to thrive in the antiglaucoma drug industry.

SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

Retrieved on: 
Freitag, Februar 3, 2023
Food, MD, Ocular hypertension, IND, Cataract, Entrepreneurship, Spyglass, Animation, University of Colorado School of Medicine, Glaucoma, Drug discovery, Intraocular pressure, New Enterprise Associates, IOP, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Sue, Bimatoprost, Intraocular lens, University, Pharmaceutical industry, IOL, Medicine

“We’ve known for decades that patient adherence to daily drop regimens is an impediment to treating ophthalmic diseases.

Key Points: 
  • “We’ve known for decades that patient adherence to daily drop regimens is an impediment to treating ophthalmic diseases.
  • These data give a clear signal that the SpyGlass drug delivery system is a breakthrough platform technology with real potential to disrupt the way our most effective therapies are administered long-term.
  • The SpyGlass drug delivery platform with bimatoprost is designed to enable every cataract surgeon the ability to provide unprecedented, multi-year glaucoma therapy at the time of routine cataract surgery.
  • The SpyGlass team is busily preparing our Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA).

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

Retrieved on: 
Freitag, Januar 6, 2023
Clinical trial, Severe cognitive impairment, Eye, Arm, Pain, Allergic conjunctivitis, BVCA, Bimatoprost, AAO, Glaucoma, Type 2 diabetes, Inflammation, Angiogenesis, Risk, Growth, Patient, DR, American Academy, Ophthalmology, AMD, Axitinib, Diabetic retinopathy, Safety, ASC, Protocol, FDA, Ocular hypertension, Visual acuity, Diagnosis, Intraocular pressure, Trial of the century, Video game, Renewable energy, Pharmaceutical industry, Dentistry, Medical device

“2022 marked a year in which Ocular made good progress against its corporate mission of becoming a mid-tier strategic within ophthalmology,” said Antony Mattessich, President and CEO.

Key Points: 
  • “2022 marked a year in which Ocular made good progress against its corporate mission of becoming a mid-tier strategic within ophthalmology,” said Antony Mattessich, President and CEO.
  • With that in mind, we initiated a Phase 1 clinical trial in diabetic retinopathy in December 2022 and anticipate presenting interim data from this trial in 2023.
  • On a preliminary basis, the Company had estimated cash and cash equivalents of $102.3 million as of December 31, 2022.
  • The Company plans to post an updated corporate presentation that can be found in the ‘Investors’ section of its corporate website on Monday, January 9, 2023.

Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)

Retrieved on: 
Dienstag, November 29, 2022
COVID-19, Growth, Humanitarian use licenses, CCO, Perception, IOP, Health Canada, Ocular hypertension, Risk, TSX Venture Exchange, Physician, Patient, Legislation, Trademark, Ophthalmology, PF, Tacrolimus, SEDAR, News, Bimatoprost, Glaucoma, OTCQB, Hope, AQS, Coronavirus, Acquisition, Video game, Pharmaceutical industry, Novartis

Health Canada approval is expected before year end 2022.

Key Points: 
  • Health Canada approval is expected before year end 2022.
  • Doug Janzen, CEO and Chairman of Aequus noted that as Sandoz transitions to a publicly traded global business their needs have evolved.
  • Aequus Pharma is anticipating a Health Canada approval by December 31, 2022 for Zimed PF in a multi-dose format.
  • Doug Janzen added that We are very excited about the Zimed PF product and its revenue potential for Aequus.

Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma

Retrieved on: 
Montag, November 7, 2022
Mont Blanc, Kepler, Bimatoprost, Patient, Exercise, Glaucoma, Optical coherence tomography, European Medicines Agency, PGA, Thermes de Saint Gervais Mont-Blanc, Severe cognitive impairment, Drainage, Clinical trial, Partnership, Hemodynamics, IOP, Bausch & Lomb, SGC, COX, Program, Company, LLC, NCX, Mercury (element), Retinal vessel analysis, Fluticasone, NO, Duane syndrome, PGAS, Euronext Paris, Ischemia, Research, AbbVie, EVP, Risk, Human, OCT, Blood, Nitric oxide, Compartment, Eye, Allergic conjunctivitis, Latanoprost, Safety, Internet, Retina, Therapy, Intraocular pressure, Ocular hypertension, NDA, Trabecular meshwork, New Drug Application, Johannes Kepler, Pharmaceutical industry, KREO, NicOx

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 development for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
  • We look forward to continuing the collaboration with Nicox to bring NCX 470 to market, said Liu Ye, Chief Executive Officer of Ocumension Therapeutics.
  • To complement our strong Chinese partnership, and maximize the potential future value of NCX 470, we are actively exploring commercial partnerships for NCX 470 in both the United States and Japanese markets, said Gavin Spencer, EVP, Chief Business Officer of Nicox.
  • NCX 470 is currently in Phase 3 development for the lowering of intraocular pressure in patients with open-angle glaucoma or elevated intraocular pressure.